Strs Ohio Raises Position in Insmed, Inc. $INSM

Strs Ohio lifted its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 590.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,454 shares of the biopharmaceutical company’s stock after acquiring an additional 25,187 shares during the quarter. Strs Ohio’s holdings in Insmed were worth $4,242,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Cravens & Co Advisors LLC acquired a new position in Insmed during the 3rd quarter worth $291,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Insmed by 70.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,598 shares of the biopharmaceutical company’s stock valued at $1,094,000 after buying an additional 3,152 shares during the period. JCIC Asset Management Inc. acquired a new position in shares of Insmed during the third quarter worth about $300,000. Yorktown Management & Research Co Inc increased its stake in shares of Insmed by 64.1% during the third quarter. Yorktown Management & Research Co Inc now owns 9,600 shares of the biopharmaceutical company’s stock worth $1,382,000 after buying an additional 3,750 shares during the period. Finally, Amalgamated Bank raised its holdings in Insmed by 12.0% in the third quarter. Amalgamated Bank now owns 14,533 shares of the biopharmaceutical company’s stock valued at $2,093,000 after acquiring an additional 1,560 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently commented on INSM. Wells Fargo & Company set a $195.00 target price on Insmed in a report on Thursday, December 18th. Citigroup reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a report on Thursday, December 18th. Wedbush set a $203.00 target price on shares of Insmed in a report on Thursday, December 18th. Finally, TD Cowen set a $241.00 price target on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $204.68.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07. Following the transaction, the chief executive officer owned 306,891 shares of the company’s stock, valued at approximately $48,774,186.63. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 1,447 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total transaction of $252,023.99. Following the sale, the chief financial officer directly owned 80,506 shares of the company’s stock, valued at approximately $14,021,730.02. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 296,799 shares of company stock worth $54,296,286 over the last three months. 3.00% of the stock is currently owned by insiders.

Insmed Stock Up 2.2%

Shares of NASDAQ INSM opened at $159.72 on Tuesday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a market capitalization of $34.06 billion, a PE ratio of -25.80 and a beta of 1.08. The firm’s 50-day moving average is $183.65 and its two-hundred day moving average is $157.39. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the prior year, the business posted ($1.27) EPS. The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. Equities analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.